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Abstract
Background: The estrogen receptors α and β (ESR1, ESR2) have been implicated in adiposity, lipid
metabolism and feeding behaviour. In this report we analyse ESR1 and ESR2 gene single nucleotide
polymorphisms (SNPs) for association with obesity. We also relate adipose tissue ESR1 mRNA
levels and ESR1 SNPs to adipocyte lipolysis and lipogenesis phenotypes.
Methods: 23 ESR1 and 11 ESR2 tag-SNPs, covering most of the common haplotype variation in
each gene according to HAPMAP data, were analysed by Chi2 for association with obesity in a
cohort comprising 705 adults with severe obesity and 402 lean individuals. Results were replicated
in a cohort comprising 837 obese and 613 lean subjects. About 80% of both cohorts comprised
women and 20% men. Adipose tissue ESR1 mRNA was quantified in 122 women and related to
lipolysis and lipogenesis by multiple regression. ESR1 SNPs were analysed for association with
adipocyte lipolysis and lipogenesis phenotypes in 204 obese women by simple regression.
Results: No ESR1 SNP was associated with obesity. Five ESR2 SNPs displayed nominal significant
allelic association with obesity in women and one in men. The two ESR2 SNPs associated with
obesity with nominal P value < 0.01 were genotyped in a second cohort where no association with
obesity was observed. There was an inverse correlation between ESR1 mRNA levels in abdominal
subcutaneous (sc) adipose tissue and basal lipolysis, as well as responsiveness to adrenoceptor
agonists independent of age and BMI (P value 0.009–0.045). ESR1 rs532010 was associated with
lipolytic sensitivity to noradrenaline (nominal P value 0.012), and ESR1  rs1884051 with
responsiveness to the non-selective beta-adrenoceptor agonist isoprenaline (nominal P value 0.05).
These associations became non-significant after Bonferroni correction.
Conclusion: ESR1 gene alleles are unlikely to be a major cause of obesity in women. A minor
importance of ESR2 on severe obesity cannot be excluded. The inverse correlation between ESR1
mRNA levels and lipolytic responsiveness to adrenoceptor agonists implies that low adipose tissue
ESR1 levels attenuate catecholamine resistance in sc fat cells of obese women hereby contributing
to loss of sc and gain of visceral fat. There is no evidence for a genetic impact of ESR1 on lipolysis
or lipogenesis.
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Background
The prevalence of obesity has reached epidemic propor-
tions and is of great public health concern. Its metabolic
complications, such as dyslipidemia and type 2 diabetes
(T2D), represent a significant cost for the society. Though
obesity is often triggered by life style, the importance of
genetic predisposition has been clearly demonstrated [1].
Defining gene alleles that are associated with obesity will
contribute to our understanding of the underlying mech-
anisms behind its development and potentially provide
therapeutic targets.
Estrogen signalling is implicated in both central, that is
regulation of food intake, and peripheral pathways pro-
tecting against adiposity. Low estrogen levels following
menopause are associated with loss of subcutaneous (sc)
and gain of visceral fat [2]. Estrogens signal via the tran-
scription factors estrogen receptors α and β (ESR1, ESR2)
[3]. Silencing of the ESR1 gene in mice renders an obese
phenotype [4]. Both ESR1 and ESR2 are expressed in the
hypothalamus, a brain area known to be involved in the
regulation of appetite and satiety [5], whilst adipocytes
express mainly ESR1  [6]. In the brain, ESR2  has been
implicated in mediating the effects of estrogen on food
intake [7]. As for peripheral effects of estrogens, hormone
replacement therapy (HRT) has been shown to inhibit
Epinephrine-stimulated lipolysis in human sc adipose tis-
sue [8]. Estrogen, signalling through ESR1, lowers the
lipolytic response in sc fat by increasing the number of
antilipolytic α2-adrenoceptors [9].
Human genetic studies support a role for the ESR genes in
regulation of body weight and certain aspects of the met-
abolic syndrome. Body mass index (BMI) (LOD 4.6, 4.2
and 2.8), waist circumference (LOD 3.3) and high-density
lipoprotein (HDL) cholesterol levels have been linked to
the chromosomal region harbouring ESR1  [10-13].
Among four investigated ESR1  polymorphisms,
rs2234693 and rs9340799 were associated with waist cir-
cumference and rs1801132 with BMI in men, but not
women [14]. In another study, ESR1 rs9340799, but not
rs2234693, was associated with waist and BMI in Japanese
women but not men [15]. Furthermore, neither
rs2234693 nor rs9340799 was associated with obesity in
Swedish women [16]. More recently, among 17 investi-
gated ESR1 polymorphisms, rs6902771, rs2431260 and
rs2175898 were associated with BMI in African Americans
[17]. Among these same 17 ESR1  polymorphisms,
rs1709183 and rs2431260 were associated with T2D in
European Americans and rs1033182 in African Americans
[18]. ESR2 has primarily been investigated in eating disor-
ders. ESR2 rs928554 and rs4986938, but not rs1256049,
have been associated with bulimic behavior [19] and
rs1256049, but not rs4986938, with anorexia nervosa
[20]. Rosenkrantz et al screened the coding region of ESR2
in probands of different weight extremes, but identified
no mutations associated with the studied phenotypes
[21].
We have recently reported that ESR1 mRNA expression
levels in sc adipose tissue and isolated adipocytes from
premenopausal women are inversely correlated with BMI
[16]. However, whether ESR1 protects against obesity or is
upregulated as a result of low BMI remains to be estab-
lished. In this report we analyse polymorphisms covering
most of the common haplotype variation in the ESR1 and
ESR2  genes for association with obesity in two large
cohorts of Swedish Caucasians. We also investigate if
ESR1 is important for lipid turnover in human adiposity
by analysing mRNA levels and gene polymorphisms for
association with adipose tissue lipolysis and lipogenesis
phenotypes in a third cohort of women., Table 1. To our
Table 1: Sample phenotypic distributions
Name Phenotype Sample 1 Obesity Sample 2 Obesity replication Sample 3a Fat cells
Obese Women (N = 581) Men (N = 124) Women (N = 689) Men (N = 148) Women (N = 216)
Age (years) 41 ± 12 45 ± 13 43 ± 11 45 ± 12 38 ± 10
BMI (kg/m2) 43 ± 5 45 ± 5 37 ± 5 45 ± 5 38 ± 5
HOMAIR 5.3 ± 5.7 10.5 ± 16.5 4.5 ± 5.7 8.2 ± 5.5 3.8 ± 2.8
Pl-cholesterol (mmol/l) 5.2 ± 1. 5.2 ± 1.2 5.3 ± 1.1 5.2 ± 1.1 5.2 ± 1.1
Pl-HDL cholesterol (mmol/l) 1.2 ± 0.3 1.0 ± 0.2 1.3 ± 0.3 1.1 ± 0.3 1.2 ± 0.3
Pl-triglycerides (mmol/l) 1.7 ± 0.9 2.3 ± 2.3 1.7 ± 1.0 2.0 ± 1.2 1.6 ± 1.0
Lean Women (N = 338) Men (N = 64) Women (N = 525) Men (N = 88) Women (N = 12)
Age (years) 50 ± 4 57 ± 8 39 ± 6 36 ± 11 33 ± 8
BMI (kg/m2) 22 ± 2 23 ± 2 22 ± 3 23 ± 1 22 ± 2
HOMAIR 1.3 ± 0.7 1.6 ± 0.8 1.3 ± 1.0 1.4 ± 0.7 1.4 ± 0.9
Pl-cholesterol (mmol/l) 5.4 ± 1.0 5.7 ± 1.1 4.7 ± 0.8 4.9 ± 1.1 4.8 ± 0.7
Pl-HDL cholesterol (mmol/l) 1.7 ± 0.4 1.4 ± 0.4 1.6 ± 0.4 1.3 ± 0.5 1.6 ± 0.4
Pl-triglycerides (mmol/l) 0.9 ± 0.5 1.5 ± 1.0 0.9 ± 0.5 1.3 ± 1.4 0.8 ± 0.2
Values are mean ± SD
a) 99 subjects overlap between sample 1 and 3.BMC Medical Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2350/8/73
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knowledge, this represents the first extensive analysis of
the impact of variations in the ESR1 and ESR2 genes for
the development of obesity.
Methods
Subjects and clinical evaluation
Samples 1 and 2 were recruited for the purpose of study-
ing genes underlying susceptibility to obesity, Table 1. In
sample 1, the lean subjects were subjects > 45 years old
and had never reached BMI > 25 kg/m2 whereas the obese
subjects had BMI > 30 kg/m2 at < 20 years of age or mor-
bid obesity, i.e. BMI > 40 kg/m2. These recruitment criteria
resulted in more young obese than lean subjects, Table 1.
The aim of selecting subjects with an extreme BMI pheno-
type in sample 1 was to enrich for a genetic impact on
obesity [22]. This was also the purpose of recruiting young
obese adults, since early onset of this disorder is believed
to have a stronger genetic component due to reduced time
of environmental impact [22]. The size of sample 1 pro-
vided 90% power to detect an allele with a frequency of
20% among controls and odds ratio (OR) ≥ 1.5 to develop
obesity assuming a threshold P value of 0.05 and domi-
nant impact on obesity [23]. 59 subjects in sample 1 were
diagnosed with T2D according to self report, but other-
wise the subjects were healthy and free of medication
according to self-report. 381 subjects in sampe 1 were also
included in our previously reported analysis of two ESR1
SNPs in obesity [16].
Sample 2 had less stringent inclusion criteria for obesity
and leanness in comparison with sample 1. Sample 2
comprised healthy non-obese subjects > 25 years old with
BMI < 25 kg/m2 and obese individuals with BMI > 30 kg/
m2, Table 1. 197 of the obese subjects in sample 2 had
hypertension, 116 T2D, and 50 dyslipidemia according to
self report. Differences in recruitment criteria resulted in
phenotypic differences between sample 1 and 2, Table 1.
The ratios between men and women were similar among
obese and lean in both samples (17–21%).
Sample 3 comprised obese and lean otherwise healthy
women recruited with the purpose of studying fat cell
function, Table 1. Lipolysis and lipogenesis were investi-
gated in 204 obese women in sample 3. 204 subjects pro-
vide approximately 75% power to detect an allele with a
frequency of 20% and R2 0.04 assuming a threshold P
value of 0.05 and dominant impact on adipocyte pheno-
types [23]. ESR1  mRNA levels in adipose tissue were
quantified in the 122 women of sample 3 for which RNA
was available. 99 women in sample 3 who met the criteria
for obesity in sample 1 were included in both samples.
All subjects above were Caucasians and at least second
generation Swedish. Obese subjects were recruited from
an outpatient center for treatment of obesity or through
local advertisement. All lean subjects were recruited
through local advertisement. All subjects came to the lab-
oratory in the morning after an overnight fast. A venous
blood sample was obtained for extraction of genomic
DNA and determination of serum insulin, as well as
plasma glucose, triglycerides, total cholesterol, and HDL
cholesterol as described [24,25]. Insulin resistance index
HOMAIR (homeostasis model assessment) was calculated
as fasting serum insulin (μU/ml) × fasting plasma glucose
(mmol/l)/22.5 [26]. The ethical committee of the Karolin-
ska University Hospital (Southern Campus) approved the
study. It was explained in detail to each participant and
her/his consent was obtained.
Lipolysis and lipogenesis investigation
In the morning after an overnight fast a sc fat biopsy was
obtained from the abdominal area by needle biopsy [27].
One part of the adipose tissue pieces was immediately fro-
zen in liquid nitrogen for subsequent RNA analysis.
Another piece was digested with collagenase to isolate fat
cells and mean fat cell weight was determined [28]. Lipol-
ysis in isolated fat cells was investigated as described
[29,30]. Briefly, cell suspensions were incubated in the
absence or presence of increasing concentrations of
noradrenaline, the non-selective β-adrenoceptor agonist
isoprenaline, or the α2-adrenoceptor selective agonist clo-
nidine. At the end of incubation an aliquot of the medium
was removed for analysis of glycerol release, which was
used as an index of lipolysis.
Lipogenesis was investigated by determining the uptake of
radio labeled glucose into lipids as described [31]. Briefly,
diluted suspensions of fat cells were incubated in the
absence or presence of increasing concentrations of crys-
talline human insulin (10-15–10-6 mol/l) for 2 h at 37°C.
Incubation was terminated by addition of sulphuric acid
and radioactivity incorporated into lipids determined.
The concentration (log mol/l) of hormone or agonist
causing half maximum effect was determined using loga-
rithmic conversion of each concentration response curve.
This value was converted to its negative form (pD2),
which reflects hormone sensitivity. The maximum effect
or responsiveness of hormone or agonist was determined
as glycerol release or glucose incorporation into lipids at
the maximum effective hormone concentration.
mRNA quantification
Total RNA was prepared from adipose tissue and reverse
transcribed as described [32]. All qPCR assays were run in
triplicates on an ABI 7500 machine (Applied Biosystems,
Foster City, CA, USA). A direct comparative method was
used for data analysis with GAPDH as control gene (User
Bulletin #2, Applied Biosystems). The amplification was
repeated twice to confirm results. ESR1 was amplified byBMC Medical Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2350/8/73
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Taqman whereas a SYBRGreen assay was applied for
GAPDH. Primer/probe sequences were as follows: ESR1
(F: 5'-AATATGCCCTTTTGCGATG-3'; R: 5'-ACAAAG-
CAAAGCTGCGACAA-3'; and Taqman probe: 5'-CTAT-
TACTGATGTGACTCGGT-3'), GAPDH (F: 5'-
TGACAACTTTGGTATCGTGGAAGG-3'; R: 5'-AGGCAG-
GGATGATGTTCTGGAGAG-3').
SNP selection and genotyping
Genotype information for ESR1 and ESR2 and regions
approximately 10 000 base pairs up- and downstream of
these genes were downloaded from HAPMAP in May
2005 [33]. Genotype data for the population of individu-
als of European ancestry were visualized using Haploview
[34]. We initially selected tag-SNPs defining all haplo-
types with frequency > 5% from the block-by-block tags
displayed in the HAPLOVIEW "Haplotypes" window.
However, sometimes these tag-SNPs were exchanged to
other SNPs on the same haplotype due to difficulties in
designing genotyping assays. In addition, in regions not
covered by common haplotypes we aimed to select one
common SNP (allele frequency > 5%) every 5 000 base
pair. No non-synonymous SNPs full-filling these criteria
were detected in the ESR genes. In selecting between dif-
ferent SNPs we prioritized (1) Golden-gate validated
assays, and (2) SNPs with high score according to Illu-
mina, which indicate that the designed Illumina genotyp-
ing assays are highly likely to work [35]. Besides the
HAPMAP SNPs we genotyped the ESR2 SNPs rs928554
and rs4986938, which previously have been associated
with feeding behavior [19].
Samples 1 and 3 were genotyped using the Illumina tech-
nology at the SNP technology platform in Uppsala
[36,35] except SNPs rs928554 and rs4986938 that were
genotyped by RFLP as described [19]. Sample 2 was geno-
typed using matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry (SEQUE-
NOM Inc., San Diego, California) as described [37]. Prim-
ers can be provided on request. The genotype call rate for
all genotyping platforms was ≥ 97% and the accuracy was
99.99% according to duplicate analysis of, on average, 2%
of the total genotypes. Hardy-Weinberg equilibrium
(HWE) calculations were performed to ensure that each
marker was within population equilibrium.
Statistical analyses
Association between ESR1 mRNA levels and lipolysis and
lipogenesis measures was assessed by multiple regression
with age and BMI as additional independent variables.
The Finetti software [38] using Pearson's goodness-of-fit
Chi2 was employed to test for allelic association between
single SNPs and obesity. ANCOVA with age and BMI as
covariates were used to analyze differences in insulin
resistance and blood lipid phenotypes between geno-
types. HOMAIR, Pl-HDL cholesterol, and Pl-triglycerides
were ln-transformed before analysis to become normally
distributed. For genetic analysis of adipocyte lipolysis and
lipogenesis, logarithm transformed phenotypes were used
as independent quantitative variables in linear regression
models. Genotypes were indicated as character (nominal)
with three levels, two different homozygous and hetero-
zygous. There was no association between the adipocyte
phenotypes and age or BMI in our sample and these vari-
ables were therefore not included in the regression model.
Haplotypes were estimated and analyzed with Haploview
[34]. LD was calculated as D'. We used HAPMAP Cauca-
sian data to define haploblock limits. Association
between haplotypes and obesity status was evaluated by
Chi2. Haplotypes with frequency < 5% and individuals
with > 50% missing genotypes were excluded in the anal-
ysis. We performed 10 000 permutations in Haploview to
adjust P values to multiple tests.
Results
ESR genotyping results
To investigate if ESR1 and ESR2 alleles contribute to sus-
ceptibility to obesity, polymorphisms covering the com-
mon variation in these genes were genotyped in sample 1,
Table 2. For ESR1, 6 out of 29 (21%) Illumina genotyping
assays failed, which is higher than the expected 10% fail-
ure rate. The majority represented Golden-gate validated
assays indicating, according to the supplier, that the fail-
ure is due to interference between different SNP assays
under the employed multiplex conditions. LD between
ESR gene SNPs is shown in Figure 1 and 2, in which hap-
loblock limits according to Caucasian HAPMAP data have
been labeled. Genotyped ESR1 SNPs built 25 haplotypes,
Table 3. These SNPs unambiguously identified 67% (20/
30) of the common (> 5%) haplotypes in the ESR1 region
in HAPMAP, representing 75% of the common haplotype
variation in ESR1 according to HAPMAP data. Remaining
ten ESR1 haplotypes in HAPMAP could in our sample not
be separated from another haplotype, that is they were
merged into five haplotypes. For ESR2, all genotyped
assays were called successfully although one SNP,
rs7154455, displayed a low genotyping call rate, 83%,
Table 2. Thus there was 100% coverage of the common
Caucasian  ESR2  haplotypes in HAPMAP, Figure 2. All
SNPs were in HWE.
Analysis of ESR SNPs and haplotypes in obesity
No ESR1 SNP displayed significant allelic association with
obesity, but one SNP, rs2813544, was associated with
obesity in analysis of homozygous subjects only, nominal
P value 0.05, Table 4. Two ESR2 SNPs, rs7154455 and
rs3020450, displayed allelic association with obesity in
the joint analysis of women and men, nominal P value
0.0003–0.01, Table 4. In permutation test, the association
between rs7154455 and obesity remained significant (PBMC Medical Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2350/8/73
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value 0.0022), whereas the result for rs3020450 became
borderline significant (P value 0.064). Both SNPs were
associated with obesity in women, but not in men. For
ESR2 SNPs rs1152582, rs1271572 and rs1269056, allelic
associations with obesity were observed in women, nom-
inal P value 0.03–0.05, but not in joint analysis of women
and men, Table 4. ESR2 SNP rs4986938 was associated
with obesity in men only, nominal P value 0.05.
rs7154455 and rs3020450 were genotyped in sample 2
where no association with obesity was observed, Table 4.
Nor was there any association with obesity in analysis of
pooled samples 1 and 2 (results not shown). No ESR SNP
was associated with HOMAIR, Pl-cholesterol, Pl-HDL cho-
lesterol, and Pl-triglycerides with P < 0.0125, and did thus
not remain significant after Bonferroni correction for
analysis of several SNPs (results not shown).
In sample 1, no ESR1 haplotype was associated with obes-
ity, Table 3. One common ESR2 haplotype, TCCC (fre-
quency 29%) at SNPs rs3020450-rs1271572-rs1887994-
rs7159462 was associated with obesity, nominal P value
0.024, Table 3. TCCC was captured by SNP rs3020450.
rs3020450 was genotyped in sample 2, where we were
unable to confirm the association observed in sample 1.
Relation of ESR1 SNPs and mRNA levels to adipocyte 
lipolysis and lipogenesis phenotypes
In 122 women with a large variation in BMI, part of sam-
ple 3, there was an inverse correlation between ESR1
mRNA levels in abdominal sc adipose tissue and adi-
pocyte basal lipolysis as well as responsiveness to
noradrenaline and more selective adrenoceptor agonists,
Figure 3. In multiple regression, including BMI, age, and
ESR1 mRNA levels as independent variables, ESR1 levels
Table 2: Genotyped ESR1 and ESR2 SNPs
Marker Gene position Chromosome position Alleles Common allele (%) Call rate (%) Chi2 of HWE
ESR1 (Chromosome 6)
rs488133 5' 152217558 C > T 68 98 0.45
rs532010 5' 152223032 A > G 65 98 0.95
rs11155813 intron 1 152241549 T > C 88 96 0.06
rs1709182 intron 2 152267471 T > C 66 96 0.81
rs1709183 intron 2 152286110 T > C 72 98 0.4
rs9340835 intron 2 152292045 G > A 68 98 0.06
rs6557170 intron 3 152295218 G > A 79 95 0.97
rs2347867 intron 3 152321964 A > G 68 98 0.17
rs9397456 intron 3 152339266 G > A 80 98 0.15
rs12154178 intron 3 152343194 A > C 72 98 0.59
rs3020317 intron 4 152370855 T > C 82 98 0.03
rs1884051 intron 4 152375393 A > G 71 98 0
rs1884054 intron 4 152383680 A > C 67 98 0.47
rs7754762 intron 4 152403651 T > A 87 97 1.61
rs7757956 intron 4 152409254 T > A 86 98 2.69
rs9340954 intron 4 152412286 T > G 70 98 2.89
rs3020368 intron 5 152463304 C > T 91 97 0.05
rs3778082 intron 6 152479778 G > A 86 95 1.76
rs2982896 intron 6 152491607 C > T 77 97 0.01
rs3020383 intron 7 152508893 G > C 92 97 0.28
rs3778099 intron 7 152510689 T > C 87 97 1.18
rs2813544 3' 152517696 A > G 79 98 0.88
rs1543403 3' 152520818 G > C 52 96 1.48
ESR2 (Chromosome 14)
rs3020450 5' 63838055 C > T 70 93 6.29a
rs1271572 5' 63831670 C > A 54 98 1.03
rs1887994 intron 1 63830364 C > A 89 97 0.28
rs7159462 intron 1 63828629 C > T 92 97 0.14
rs1269056 intron 3 63813643 C > T 56 97 1.3
rs7154455 intron 3 63806413 G > C 64 83 0.23
rs1256061 intron 7 63773346 G > T 50 97 1.89
rs1256063 intron 7 63771970 G > A 91 94 0.27
rs4986938 3' 63769569 G > A 62 100 0.56
rs928554 3' 63763948 A > G 56 100 2.8
rs1152582 3' 63762383 C > G 56 98 0.71
a) HWE among controls n.s.BMC Medical Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2350/8/73
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were an independent factor regulating basal lipolysis (P =
0.018), as well as responsiveness to noradrenaline (P =
0.013), Table 5. Association between ESR1 mRNA levels
and lipolytic responsiveness was stronger for the α2-
adrenoceptor selective agonist clonidine (P = 0.009), than
for the non-selective β-adrenoceptor agonist isoprenaline
(P = 0.045), Table 5. There was no association between
ESR1 mRNA levels and sensitivity of lipolysis to adreno-
ceptor agonists, nor between ESR1  mRNA levels and
measures of lipogenesis. We next analysed ESR1 SNPs for
impact on adipocyte lipolysis and lipogenesis in the 204
obese women of sample 3, for which these phenotypes
had been investigated. No SNP was associated with basal
lipolysis (results not shown). One ESR1 SNP, rs532010,
was associated with lipolytic sensitivity to noradrenaline,
nominal P value 0.012, Table 6. Another ESR1  SNP,
rs1884051, was associated with responsiveness to the
non-selective beta-adrenoceptor agonist isoprenaline,
nominal P value 0.05. These SNP associations became
non-significant after Bonferroni correction for analysis of
several SNPs. No ESR1 SNP was associated with lipogene-
sis (results not shown).
Discussion
Estrogen signalling has been implicated in regulation of
human adiposity [4]. There is evidence that ESR1 acts in
fat cells, whereas ESR2 mediates the effects of estrogen on
food intake [7,9]. We here report that ESR1 mRNA levels
in adipose tissue were inversely correlated with basal
lipolysis and adrenoceptor responsiveness in obese
women. In sample 1, two ESR2 SNPs were associated with
obesity with nominal P value < 0.01. However, these asso-
ciations were not confirmed in sample 2. No ESR1 SNP
displayed allelic association with obesity or lipolysis.
Although no ESR1 SNP displayed allelic association with
obesity, we cannot completely exclude an impact of ESR1
alleles on female obesity since genotyped SNPs failed to
capture a few common haplotypes in the region of the
ESR1gene.
Two ESR2 SNPs, rs7154455 and rs3020450 were associ-
ated with obesity with nominal P value < 0.01. The call
rate for rs7154455 was only 83% adding some uncer-
tainty to this association. rs7154455 and rs3020450 were
genotyped in sample 2. In sample 2, as well as in pooled
analysis of sample 1 and 2, no association with obesity
was observed. This suggests that the allelic association of
LD (D') between ESR1 SNP and haploblocks according to Caucasian HAPMAP data Figure 1
LD (D') between ESR1 SNP and haploblocks according to Caucasian HAPMAP data.BMC Medical Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2350/8/73
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the two ESR2 SNPs in sample 1 was spurious. However,
since recruitment criteria for sample 2 were based on less
stringent definitions of obesity and leanness, and
included subjects with metabolic complications of obes-
ity, we cannot exclude that the ESR2 SNPs have a modest
impact on more extreme forms of uncomplicated obesity
such as in sample 1. In addition, this study was not
designed to study potential gene-environment interac-
tions. This is particularly important for ESR2, which has
been implicated in mediating the effects of estrogen on
food intake. Furthermore, our cohort of men was too
small to exclude a male-specific impact of ESR1 and ESR2
on obesity. This might explain the difference between our
results and the association of ESR1 and male obesity pre-
viously reported [14].
We have reported before that ESR1  rs2234693 and
rs9340799 are not associated with obesity in a cohort of
Swedish women partially overlapping with the cohort
studied in this project [16]. We therefore did not genotype
rs2234693 and rs9340799 in this study. ESR1 rs1801132,
reported to be associated with BMI in men in the Framing-
ham Heart Study [14], is according to the Caucasian HAP-
MAP data on the same haplotype as rs9397456, which
was genotyped in this project. We did not genotype the
three ESR1 SNP reported to be associated with BMI in
African Americans [17]; however the reported BMI associ-
ated SNP rs6902771 is according to HAPMAP on the same
haplotype as rs2234693, which we genotyped. We geno-
typed rs1709183, but not rs2431260, reported to be asso-
ciated with T2D [18]. Finally, we genotyped rs928554 and
rs4986938, but not rs1256049, implicated in eating disor-
ders [19,20]. SNPs genotyped in our present project, that
previously have been associated with obesity related and
eating disorders, were not associated with obesity in the
present project.
Human obesity is associated with increased rate of basal
lipolysis in all fat depots and lipolytic resistance to cate-
cholamines in sc fat [39]. Our finding that ESR1 mRNA
levels in adipose tissue are inversely correlated with rate of
basal lipolysis might suggest that low adipose tissue ESR1
levels, as observed in obesity [16], increases basal lipoly-
sis. In addition, the inverse correlation between ESR1
mRNA levels and lipolytic responsiveness to catecho-
lamines implies that low adipose tissue ESR1  levels
among obese counteracts catecholamine resistance in sc
fat cells of obese women. Catecholamine resistance
among obese is specific to sc fat [39]. Attenuation of lipo-
lytic catecholamine resistance may explain why low estro-
LD (D') between ESR2 SNP and haploblocks according to Caucasian HAPMAP data Figure 2
LD (D') between ESR2 SNP and haploblocks according to Caucasian HAPMAP data.BMC Medical Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2350/8/73
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gen signalling is associated with fat redistribution with
loss of sc and gain of visceral fat [2]. In our analyses, there
was no evidence for a genetic impact of ESR1 on lipolysis
or lipogenesis.
Conclusion
Common ESR1 gene alleles are unlikely to contribute to
obesity in women, whereas a minor importance of ESR2
on severe obesity cannot be excluded. The male subset in
our sample was too small to exclude that ESRs have an 
Table 3: Association of ESR1 and ESR2 haplotypes with obesity
Cases Controls
Haploblock % Specific haplotype (n) Other (n) Specific haplotype (n) Other (n) P value
ESR1
rs488133-rs532010-rs11155813
CGT 34 449 917 288 508 0.12
TAT 33 455 911 250 546 0.37
CAT 21 285 1081 167 629 0.96
CAC 11 158 1208 82 714 0.36
rs1709182
T 67 925 441 516 282 0.14
C 33 441 925 282 516 0.14
rs6557170-rs2347867
GA 68 916 450 549 249 0.40
AG 21 299 1067 165 633 0.52
GG 11 151 1215 84 714 0.68
rs12154178
A 18 976 390 575 223 0.76
C 28 390 976 223 575 0.76
rs3020317
T 82 1116 250 652 146 1.00
C 18 250 1116 146 652 1.00
rs1884054
A 67 920 446 531 267 0.70
C 33 446 920 267 531 0.70
rs7754762-rs7757956-rs9340954-rs3020368
TTTC 69 947 420 557 239 0.75
ATGC 13 185 1181 99 697 0.47
TAGT 8 113 1253 69 727 0.77
TAGC 5 67 1299 43 753 0.59
rs3778082-rs2982896
GC 63 862 502 502 296 0.90
GT 23 310 1054 197 601 0.30
AC 14 192 1172 99 699 0.27
rs2813544-rs1543403
AC 48 640 727 396 402 0.21
AG 31 419 948 248 550 0.82
GG 21 301 1065 152 646 0.10
ESR2
rs3020450-rs1271572-rs1887994-rs7159462
CACC 46 639 727 346 452 0.12
TCCC 29 372 994 254 544 0.024*
CCAC 11 153 1213 79 719 0.33
CCCT 8 116 1251 65 733 0.83
CCCC 6 81 1285 49 749 0.86
rs1256061-rs1256063
TG 50 671 689 401 397 0.68
GG 41 547 814 331 467 0.57
GA 10 142 1218 66 732 0.10
rs4986938-rs928554-rs1152582
GGG 44 619 747 333 465 0.10
AAC 38 502 864 310 488 0.32
GAC 18 233 1133 149 649 0.35B
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Table 4: Association between ESR SNPs and obesity in samples 1 and 2a
Gene SNP Controls (n) Cases (n) Allele Frequency Heterozygous Homozygous Recessive model Armitage's trend 
test
22b 21 11 22 21 11 [2]<-> [1]c P value [22]<-> [12] P value [22]<-> [11] P value [11+12]<-> [22] P value OR P value
Sample 1
ESR1 rs2813544 10 134 255 33 242 408 0.82 
[0.66–1.02]
0,08 0.55 
[0.26–1.14]
0,11 0.48 
[0.24–1.00]
0,05 0.51 
[0.25–1.04]
0,06 0,79 0,07
Women 8 114 213 29 194 339 0.83 
[0.66–1.06]
0,13 0.47 
[0.21–1.06]
0,06 0.44 
[0.20–0.98]
0,04 0.45 
[0.20–1.00]
0,04 0,79 0,13
Men 2 20 42 4 48 69 0.77 
[0.45–1.31]
0,33 1.20 
[0.20–7.08]
0,84 0.82 
[0.14–4.68]
0,82 0.94 
[0.17–5.30]
0,95 0,78 0,31
ESR2 rs7154455 107 167 47 273 260 62 0.70 
[0.57–0.85]
0,0003 0.61 
[0.45–0.82]
0,001 0.52 
[0.33–0.80]
0,003 0.59 
[0.44–0.78]
0,0002 0,7 0,0003
Women 84 144 43 223 219 45 0.63 
[0.51–0.78]
0,00003 0.57 
[0.41–0.80]
0,0008 0.39 
[0.24–0.64]
0,0001 0.53 
[0.39–0.73]
0,00007 0,62 0,00002
Men 23 23 4 50 41 17 1.18 
[0.71–1.97]
0,51 0.82 
[0.40–1.67]
0,58 2.0 [0.59–6.46] 0,27 0.99 
[0.50–1.94]
0,97 1,26 0,53
rs3020450 177 163 44 353 237 59 0.78 
[0.64–0.94]
0,01 0.73 
[0.56–0.95]
0,02 0.67 
[0.44–1.03]
0,07 0.72 
[0.56–0.92]
0,01 0,8 0,01
Women 147 139 41 288 202 42 0.72 
[0.58–0.89]
0,002 0.74 
[0.55–1.00]
0,05 0.52 
[0.33–0.84]
0,007 0.69 
[0.52–0.91]
0,009 0,73 0,003
Men 30 24 3 65 35 17 1.17 
[0.71–1.94]
0,54 0.67 
[0.34–1.32]
0,25 2.61 
[0.71–9.61]
0,14 0.89 [
0.47–1.68]
0,72 1,32 0,57
ESR2 Women
rs1152582 54 171 110 127 274 161 0.80 
[0.66–0.98]
0,03 0.68 
[0.47–1.00]
0,04 0.62 
[0.42–0.93]
0,01 0.66 
[0.46–0.94]
0,02 0,8 0,03
rs1271572 59 172 104 130 281 151 0.82 
[0.68–1.00]
0,05 0.74 
[0.52–1.06]
0,1 0.66 
[0.44–1.00]
0,04 0.71 
[0.50–1.00]
0,05 0,82 0,04
rs1269056 53 175 107 127 275 158 0.81 
[0.66–0.98]
0,03 0.66 
[0.45–0.95]
0,03 0.62 
[0.41–0.92]
0,02 0.64 
[0.45–0.91]
0,01 0,8 0,03
ESR2 Men
rs4986938 4 30 30 20 59 45 0.64 
[0.40–1.00]
0,05 0.39 
[0.12–1.26]
0,11 0.30 
[0.09–0.96]
0,04 0.35 
[0.11–1.06]
0,05 0,6 0,05
Sample 2
ESR2 rs3020450 326 245 41 410 332 60 1.08 
[0.91–1.27]
0,39 1.08 
[0.86–1.34]
0,51 1.16 
[0.76–1.78]
0,48 1.09 
[0.88–1.34]
0,42 1.08 0,38
Women 273 216 35 346 282 53 1.06 
[0.89–1.27]
0,42 1.03 
[0.81–1.31]
0,81 1.20 
[0.76–1.88]
0,44 1.05 
[0.84–1.32]
0,65 1.07 0,51
Men 53 29 6 64 50 7 1.18 
[0.75–1.86]
0,46 1.42 
[0.80–2.56]
0,23 0.97 
[0.31–3.05]
0,95 1.35 
[0.77–2.35]
0,29 1.11 0,46
rs7154455 318 248 46 399 341 63 1.06 
[0.90–1.26]
0,45 1.10 
[0.88–1.37]
0,42 1.09 
[0.73–1.64]
0,67 1.09 [
0.89–1.35]
0,40 1.06 0,44
Women 268 216 40 337 287 57 1.06 
[0.89–1.27]
0,52 1.06 
[0.83–1.34]
0,65 1.13 
[0.73–1.75]
0,57 1.07 
[0.85–1.34]
0,57 1.06 0,52
Men 50 32 6 62 54 6 1.11 
[0.71–1.73]
0,64 1.36 
[0.77–2.42]
0,29 0.81 
[0.24–2.65]
0,72 1.27 
[0.73–2.21]
0,74 1.05 0,63
a) Shown are SNPs with P value < 0.05 in at least one analysis.
b) 1 and 2 represent the two alleles of each SNP.
c) OR (95% confidence interval)BMC Medical Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2350/8/73
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ESR1 mRNA levels in abdominal sc adipose tissue plotted against (A) basal lipolysis, response to (B) noradrenaline, (C) the  non-selective β-adrenoceptor agonist isoprenaline, and (D) the α2-adrenoceptor selective agonist clonidine Figure 3
ESR1 mRNA levels in abdominal sc adipose tissue plotted against (A) basal lipolysis, response to (B) noradrenaline, (C) the 
non-selective β-adrenoceptor agonist isoprenaline, and (D) the α2-adrenoceptor selective agonist clonidine.
Table 5: Regression of basal lipolysis and responsiveness to adrenoceptor agonist on ERS1 mRNA levels
Coefficient ± SE Std. Coeff. T-value P value
Basal lipolysis
Intercept 2.34 ± 4.54 2.34 0.51 0.61
ESR1 (AU) -3.90 ± 1.62 -0.20 -2.40 0.018
BMI (kg/m2) 0.44 ± 0.10 0.39 4.61 <0.0001
Age (years) -0.14 ± 0.08 -0.15 -1.86 .065
Response to noradrenaline
Intercept 13.84 ± 6.40 13.84 2.16 .033
ESR1 (AU) -5.72 ± 2.26 -0.21 -2.53 .013
BMI (kg/m2) 0.58 ± 0.13 0.37 4.38 <0.0001
Age (years) -0.22 ± 0.11 -.174 -2.12 .036
Response to isoprenaline
Intercept 15.44 ± 8.72 15.44 1.77 0.079
ESR1 (AU) -6.31 ± 3.11 -0.18 -2.03 0.045
BMI (kg/m2) 0.78 ± 0.18 0.37 4.28 <.0001
Age (years) -0.16 ± 0.14 -0.10 -1.14 0.26
Response to clonidine
Intercept 0.99 ± 0.92 0.99 1.08 0.28
ESR1 (AU) -0.87 ± 0.33 -0.23 -2.65 0.0091
BMI (kg/m2) 0.07 ± 0.02 0.31 3.57 0.0005
Age (years) -0.02 ± 0.02 -0.08 -1.00 0.32BMC Medical Genetics 2007, 8:73 http://www.biomedcentral.com/1471-2350/8/73
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impact on obesity in men. Low ESR1 mRNA levels in adi-
pose tissue may counteract catecholamine resistance in fat
cells of obese women hereby contributing to loss of sc and
gain of visceral fat [39]. In our analysis of obese women
there was no evidence for a genetic impact of ESR1 on
lipolysis or lipogenesis. In future research, it will be
important to investigate if there are interactions between
ESR2 gene alleles and environmental factors such as food
intake.
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